NCT00535028View on ClinicalTrials.gov

A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study)

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2005

Study Completion Date

May 31, 2005

Conditions
Allergic Asthma
Interventions
DRUG

AER 001

AER 001 25 mgs s.c. once daily for 28 days

DRUG

placebo

sterile saline

Trial Locations (1)

SE1 1YR

Guy's Drug Research Unit, Quintiles, Ltd., 6 Newcomen Street London

Sponsors

Lead Sponsor

Aerovance, Inc.
All Listed Sponsors
collaborator

Quintiles, Inc.

INDUSTRY

lead

Aerovance, Inc.

INDUSTRY

NCT00535028 - A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study) | Biotech Hunter | Biotech Hunter